Evidence map›Paper›PMID 39116226›Full record

ArticleScience (New York, N.Y.)2024

Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates.

Fathima N Nagoor Pitchai, Elizabeth J Tanner, Neha Khetan, Gustavo Vasen, Clara Levrel, Arjun J Kumar, Shilpi Pandey, Tracy Ordonez, Philip Barnette, David Spencer and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Fathima N Nagoor Pitchai *Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA.
Elizabeth J Tanner *Gladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA.
Neha KhetanGladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA.
Gustavo VasenGladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA.
Clara LevrelGladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA.
Arjun J KumarGladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA.
Shilpi PandeyOregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Tracy OrdonezOregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Philip BarnetteOregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
David SpencerOregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Seung-Yong JungGladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA.
Joshua GlazierGladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA.
Cassandra ThompsonGladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA.
Alicia Harvey-Vera
Hye-In SonGlobal Health Sciences, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Hye-In SonGladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA.
Steffanie A StrathdeeGlobal Health Sciences, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Leo HolguinGlobal Health Sciences, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Ryan UrakCenter for Gene Therapy, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
John BurnettCenter for Gene Therapy, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
William BurgessVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Kathleen Busman-SahayVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Jacob D EstesVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Ann HessellOregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Christine M FennesseyAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Nancy L HaigwoodOregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Leor S WeinbergerGladstone Center for Cell Circuitry, University of California, San Francisco, CA, USA.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6M
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Marketsand Drug TourismR01DA049644 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI STRATHDEE, STEFFANIE A. · 2020 to 2024
$8.2M
Modulating Stochastic Gene Expression for Cell-fate Control and TherapeuticsR37AI109593 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI WEINBERGER, LEOR S · 2021 to 2025
$6.2M
Viral Testing CoreU42OD010426 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Samuel Peterson · 2013 to 2026
$6.0M
A Gene Drive Therapy for HIV: Single-Administration Intervention for High-RiskGroupsDP1DA051144 · NIDA · J. DAVID GLADSTONE INSTITUTES · PI WEINBERGER, LEOR S · 2020 to 2024
$5.7M
Developing Transmissible Antivirals by Exploiting Gene-Expression CircuitryDP2OD006677 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WEINBERGER, LEOR S · 2009 to 2009
$2.3M
BD FACSAria II Flow CytometerS10RR028962 · NCRR · J. DAVID GLADSTONE INSTITUTES · PI CAVROIS, MARIELLE · 2011 to 2011
$544k
NCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCRR NIH HHS S10 RR028962NIAID NIH HHS P30 AI027763NIAID NIH HHS R37 AI109593NIDA NIH HHS DP1 DA051144NIDA NIH HHS R01 DA049644NIH HHS DP2 OD006677NIH HHS P51 OD011092NIH HHS U42 OD010426
6 · The paper itself

Abstract

Antiviral therapies with reduced frequencies of administration and high barriers to resistance remain a major goal. For HIV, theories have proposed that viral-deletion variants, which conditionally replicate with a basic reproductive ratio [R

Indexed as

Artificial Virus-Like ParticlesGene DeletionHIV-1HIV InfectionsViral InterferenceVirus ReplicationAnimalsBasic Reproduction NumberDisease Models, AnimalGenetic EngineeringHumansMacaca mulattaMiceProof of Concept StudySimian Immunodeficiency VirusViremia

Identifiers

PMID39116226
PMCPMC11545966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.